II. Indications
III. Contraindications
-
Allergic Reaction to Clevidipine or its components
- Cross reactivity with soy and soybeans, egg and egg product allergies
- Lipid Metabolism defect
- Severe Aortic Stenosis
-
Pheochromocytoma
- Hypertensive Emergency management with Alpha Adrenergic Receptor antagonist with or without Beta Blocker
IV. Mechanism
- Parenteral Dihydropyridine Calcium Channel Blocker
- Arterial Smooth Muscle dilation
- Decreases Peripheral Vascular Resistance (Afterload reduction)
- Minimal to no effect on Preload, cardiac conduction, or cardiac contractility
- However Calcium Channel Blockers may have negative inotropic effects
V. Pharmacokinetics
- Onset: <2 minutes (systolic Blood Pressure response)
- Half-Life: 1 minute
- Return to baseline Blood Pressure 5-15 minutes after discontinuing infusion
VI. Dosing
- Start: 1-2 mg/hour IV infusion
- Titrate: Double dose (as often as every 90 seconds, then every 5-10 min) until approaching target Blood Pressure
- Blood Pressure drops 2-4 mmHg for every 1-2 mg/h
- Typical maintenance dose 4-6 mg/h
- Half of maximal effect reached at 10 mg/h
- Typical maximum dose 16 mg/h (absolute maximum dose 32 mg/h)
VII. Adverse Effects
- Common
- Serious
- Hypotension
- Reflex Tachycardia
- Congestive Heart Failure Exacerbation
- Rebound Hypertension
- Prevent by transitioning onto other antihypertensives before discontinuing Clevidipine
VIII. References
- Kristensen and LoVecchio (2020) Crit Dec Emerg Med 34(9): 28
- Tarascon Pharmacopeia, accessed 2/11/2021
Images: Related links to external sites (from Bing)
Related Studies
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C118563 |
| SnomedCT | 439471002, 439624003 |
| English | Clevidipine (substance), Clevidipine, Clevidipine (product), clevidipine, CLEVIDIPINE, butyroxymethyl methyl 4-(2',3'-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate |
| Spanish | clevidipino, clevidipino (sustancia), clevidipino (producto) |
